Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: Urinary Bladder Neoplasms trials
The registry lists 10 Urinary Bladder Neoplasms studies with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor. 3 are open to participants now and 0 have results posted.
Phase 2 8No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder CancerNot yet recruitingNCT06751667Not applicable
- Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingNCT06528483Phase 2
- Quantifying Systemic Immunosuppression to Personalize Cancer TherapyRecruitingNCT05621837
- Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR StudyWithdrawnNCT03832673Phase 2
- hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"Status unknownNCT03824691Phase 2
- Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder CarcinomaCompletedNCT02736266Phase 2
- Alisertib in Chemotherapy-pretreated Urothelial CancerCompletedNCT02109328Phase 2
- PF-03446962 in Relapsed or Refractory Urothelial CancerCompletedNCT01620970Phase 2
- Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the BladderStatus unknownNCT01222676Phase 2
- Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to TreatmentCompletedNCT01031875Phase 2